Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.59 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 4/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.52 |
| ▸ | CDK9 | P50750 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 3/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611706 | 0.88 | ABL1 (0.52) | CDK2CDK4GSK3BABL1CDK9 | |
| SCHEMBL3614099 | 0.83 | ABL1 (0.63) | GSK3BABL1CCNT1CDK9SRC | |
| SCHEMBL3616129 | 0.82 | ABL1 (0.56) | GSK3BABL1SRCSYKBCR | |
| SCHEMBL3609221 | 0.81 | ABL1 (0.57) | CDK2CDK4GSK3BABL1CDK9 | |
| SCHEMBL3613419 | 0.79 | ABL1 (0.57) | CDK2CDK4GSK3BABL1CDK9 | |
| SCHEMBL12509694 | 0.79 | IKBKB (0.62) | CDC7CDK19CDK2CDK4GSK3B | |
| SCHEMBL4381439 | 0.79 | CDC7 (0.71) | CDC7CDK19CDK2ABL1CCNT1 | |
| SCHEMBL12423443 | 0.78 | IKBKB (0.61) | CDC7CDK19CDK2CDK4GSK3B | |
| SCHEMBL3598695 | 0.77 | JAK2 (0.56) | GSK3BABL1CDK9SRCEGFR | |
| SCHEMBL3610161 | 0.74 | CDK9 (0.56) | CDK2CDK4GSK3BABL1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDC7 4102/4885CDK19 3733/4885CDK2 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.